ArticleImmunoTargets and therapy2026
Risk and Management of Bowel Obstruction in Colorectal Cancer Patients Undergoing Immunotherapy: A Cross-Sectional Multicenter Study.
Article in ImmunoTargets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bowel obstruction in mismatch repair-deficient colorectal cancer with excellent response to immunotherapy: a case series.Annals of coloproctology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Despite the remarkable efficacy of immunotherapy for mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) colorectal cancer (CRC), patients may still develop bowel obstruction during tumor regression. Methods: The study cohort included CRC patients who received immunotherapy at four medical centers. Bowel obstruction risk was assessed, and clinicopathological and molecular features were recorded. A Bayesian model was used to identify risk factors. Results: A total of 214 patients were reviewed, with 196 patients meeting the eligibility criteria. Bowel obstruction occurred in 22 patients (10.3%) during immunotherapy. Obstruction was more commonly observed in patients with T4 stage tumors ( Conclusion: Bowel obstruction was common in CRC patients receiving immunotherapy. This risk may be suggested by two clinical features at baseline. Obstructions often occurred after the initial response but before the best overall response. Early detection and proper management may help to prevent or reduce obstructions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.